Publication:
The pharmacogenomics of vincristine-induced peripheral neuropathy in pediatric acute lymphoblastic leukemia patients in Serbia – a single center experience

dc.contributor.authorRistivojević, Bojan (57216549129)
dc.contributor.authorKotur, Nikola (54961068500)
dc.contributor.authorStanković, Biljana (35785023700)
dc.contributor.authorGašić, Vladimir (57095898600)
dc.contributor.authorLazić, Jelena (7004184322)
dc.contributor.authorPavlović, Sonja (7006514877)
dc.contributor.authorZukić, Branka (26030757000)
dc.date.accessioned2025-06-12T13:05:59Z
dc.date.available2025-06-12T13:05:59Z
dc.date.issued2022
dc.description.abstractIntroduction/Objective Vincristine (VCR) is one of the key drugs in current treatment protocols for pediatric acute lymphoblastic leukemia (ALL). By destabilizing microtubules, VCR arrests cells in metaphase, inducing apoptosis of malignant cells. VCR also causes axonal degradation and impairment of axonal transport, which leads to VCR-induced peripheral neuropathy (VIPN). This study aimed to investigate the association of five variants in pharmacogenes involved in VCR me-tabolism with VIPN in Serbian ALL children. We also wanted to discover candidate pharmacogenomic markers of VIPN in Serbian population. Methods PCR and sequencing-based methodology was used to detect variants in CYP3А5, CEP72, ACTG1, MIR3117, and MIR4481 genes. Statistical analyses were performed for investigating their association with VIPN in 56 pediatric ALL patients. Population VCR pharmacogenomics analysis of 17 pharmacogenes from in-house next-generation sequencing data was also done. Data on allele frequency distribution for the European population were extracted from public databases. Results During the treatment, 17.86% of patients developed VIPN. Association analyses have shown that none of the genetic variants contributed to the occurrence of VIPN in our study. Population phar-macogenomics study did not reveal valid candidate pharmacovariants for VIPN. Our results suggested that pre-emptive pharmacogenetic testing for VCR is not applicable presently. Conclusion More comprehensive approaches are needed to identify the panel of genes that could explain the VIPN development after VCR administration in ALL patients. Utilizing better designed genome-wide association studies and more robust artificial intelligence-based tools would provide a panel of pharma-cogenes for pre-emptive tests of VIPN to individualize therapy for ALL in children. © 2022, Serbia Medical Society. All rights reserved.
dc.identifier.urihttps://doi.org/10.2298/SARH210813099R
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85127223281&doi=10.2298%2fSARH210813099R&partnerID=40&md5=ca66b9bfdd909211e1e0b44f9be5683a
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/3809
dc.subjectacute lymphoblastic leukemia
dc.subjectpharmacogenomics
dc.subjectvincristine
dc.subjectvincristine-induced peripheral neuropathy (VIPN)
dc.titleThe pharmacogenomics of vincristine-induced peripheral neuropathy in pediatric acute lymphoblastic leukemia patients in Serbia – a single center experience
dspace.entity.typePublication

Files